

DDFU/DRUGU (Derwent Drug File)

DDFU Derwent Drug File Standard
 DRUGU Derwent Drug File for Subscribers

Subject Coverage All aspects of drugs:

- Analysis
- Biochemistry
- Galenics
- Metabolism
- Pharmacokinetics
- Pharmacology
- Structure-Activity Relationships
- Synthesis
- Therapeutics and Adverse Effects
- Toxicology

File Type Bibliographic, Structure

Features

Thesaurus	Controlled Term (/CT)			
Alerts (SDI)	Weekly or monthly (weekly is the default)			
CAS Registry Numbers®	<input checked="" type="checkbox"/>	Page Images	<input type="checkbox"/>	STN AnaVist <input type="checkbox"/>
Keep & Share	<input checked="" type="checkbox"/>	SLART	<input checked="" type="checkbox"/>	STN Easy <input checked="" type="checkbox"/>
Learning Database	<input type="checkbox"/>	Structures	<input checked="" type="checkbox"/>	STN Viewer <input type="checkbox"/>

Record Content

- Besides the literature segment, the database also contains the Derwent Drug Registry as a file segment, which is structure-searchable in the subscriber version (file DRUGU).
- In addition to bibliographic information, literature records contain Derwent's abstract (and extension abstract in file DRUGU only), controlled term indexing, structure codes (file DRUGU only), as well as CAS Registry Numbers and Enzyme Commission Numbers where applicable.
- The substance records in the registry segment contain common drug and Derwent Drug Registry names, CAS Registry Numbers, indexing terms, structure codes, and displayable and searchable structure graphics (DRUGU only).

File Size

- Literature segment more than 1.5 million records (02/12)
- Registry segment more than 157,956 records (02/12)

Coverage 1983–present

Updates Weekly

Language English

**Database
Producer**

Thomson Reuters (Scientific) Ltd.
The Johnson Building
77 Hatton Garden
London EC1N 8JS
United Kingdom
Copyright Holder: Thomson Reuters

Phone: +44 20 7433 4000
Fax: +44 20 7433 4001
Helpdesk: +44 20 7433 4999
E-mail: ts.support.emea@thomsonreuters.com

Sources

1,100 Medical and scientific journals and conference proceedings

User Aids

- Derwent Drug File Thesaurus *
 - Product Description *
 - Journal List and Selection Guidelines *
 - Work Books *
 - Building and Searching Structures on STN
 - Online Helps (HELP DIRECTORY lists all help messages available)
 - STNGUIDE
- * available from the producer

Clusters

- | | |
|---|--|
| <ul style="list-style-type: none"> • ALLBIB • AUTHORS • BIOSCIENCE • CASRNS (file DRUGU only) • CORPSOURCE • FORMULATIONS | <ul style="list-style-type: none"> • MEDICINE • PHARMCOLOGY • STRUCTURE (file DRUGU only) • TOXICOLOGY <p>STN Database Clusters information (PDF).</p> |
|---|--|

**Related
Databases**

- DDFB
- DRUGB
(contain the data from 1964-1982)

Pricing

- See the [STN Price List](#) or enter HELP COST at an arrow prompt.

DDFU/DRUGU contain two database segments each. A search may be restricted to one segment by using the field /FS or by defining a specific RANGE (RANGE=LIT for literature, RANGE=REG for the registry segment)

Search and Display Field Codes

Literature Segment

Fields that allow left truncation are indicated by an asterisk (*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index* (contains single words from title (TI), controlled term (CT), abstract (AB), CAS Registry Numbers, and Enzyme Commission Numbers. In File DRUGU additionally single words from the extension abstract (ABEX))	None or /BI	S ANTI-TUMOR(L)TOXIC EFFECT# S CYCLOPHOSPHAMIDE S 443-48-1 S EC-2.3.1.37	TI, AB, ABEX (1), CT
Accession Number	/AN	S 1994-00609/AN	AN
Author	/AU	S TEELMANN K/AU	AU
Availability of Document (2) (Reprint Address)	/AV	S NIPPON ROCHE KAJIWARA/AV	AV
CAS Registry Number	/RN	S 443-48-1/RN	CT
Classification Code (2) (code and text)	/CC	S 73/CC S TRIAL PREPARATIONS/CC	CC
Controlled Term (3,4) (limited by roles)	/CT	S MARROW-DISEASE/CT S MARROW-DISEASE *AE/CT (L)CYCLOPHOSPHAMIDE *AE/CT	CT
Corporate Source (2)	/CS	S NIPPON ROCHE/CS	CS
Derwent Drug Registry Name (5) (link to registry segment)	/DDRN	S FALIMINT/DDRN	CT
Document Type (code and text)	/DT (or /TC)	S JOURNAL/DT S J/DT	DT
Entry Date (6)	/ED (or /UP)	S L8 AND ED>19980100	not displayed
Enzyme Commission Number	/EC	S EC-2.3.1.37/EC	CT
Field Availability	/FA	S L7 AND AB/FA	FA
File Segment	/FS	S L5 AND LIT/FS S E1-10 AND REG/FS	FS
International Standard (Document) Number (CODEN and ISSN)	/ISN	S 0020-7136/ISN S IJCNAW/ISN	SO
Journal Title	/JT	S INT J CANCER?/JT	SO
Language (ISO code and text)	/LA	S L7 AND DE/LA S GERMAN/LA	LA
Location (2)	/LO	S (BASLE OR BASEL)/LO S KANAGAWA JAP?/LO	LO
Multipunch Code (1,7)	/MPC	S 107 084 109 120/MPC S 107 *S 084 *S 109 *S 120 *S/MPC	MPC
Publication Year (6)	/PY	S 1990-1992/PY	SO
Source (contains journal title, ISSN, CODEN, collation, and reprint address)	/SO	S INT J CANCER?/SO S IJCNAW/SO S 0020-7136/SO	SO
Subject Heading (code and text)	/SH	S S/SH AND L10 S ADVERSE EFFECTS/SH	SH

(1) This field is available in the Derwent Subscriber file DRUGU only

(2) Search with implied (S) proximity is available in this field.

(3) There are nine roles available in field /CT to limit a search to a particular aspect of a drug or a disease: AE Adverse Effects, DI Drug Interactions, DM Drug Metabolism, FT Further Term (assigned when no other role assigned), OC Other Context, PH Pharmacology, RC Reference Compound, RN Registry Name, TR Treatment.

DDFU/DRUGU

- (4) Controlled terms concerning the same drug in a record are linked by (L) proximity.
 (5) To obtain related registry records, SELECT DDRN and search the resulting E-number(s) by adding 'AND REG/FS' (e.g. => S E1-10 AND REG/FS).
 (6) Numeric search field that may be searched using numeric operators or ranges.
 (7) Search with implied (L) proximity is available in this field. Multipunch codes concerning the same drug in a record are linked by (L) proximity.

Registry Segment

Fields that allow left truncation are indicated by an asterisk (*).

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index* (contains single words from controlled term (CT), Derwent drug registry (DDRN) and drug names (DDN), substructure terms (SS), note (NTE), and CAS Registry Numbers)	None or /BI	S FORFENIMEX S A-1576 S ALDOSE-REDUCTASE-INHIBITORS S 50-33-9 S EC-1.11.1.6	CT, DDRN, DDN, NTE, SS, RN
Accession Number CAS Registry Number Controlled Term (pharmacology terms) Derwent Drug Name	/AN /RN /CT /DDN	S 9606/AN S 50-33-9/RN S ALDOSE-REDUCTASE-INHIBITORS/CT S P-8977/DDN S PACHYBASIN/DDN S FORPHECOL/DDN	AN RN CT DDN
Derwent Drug Registry Name (1) (link to literature segment) Entry Date (2)	/DDRN (or /CT) /ED (or /UP)	S L12 AND ED>19980100	DDRN not displayed
Enzyme Commission Number File Segment	/EC /FS	S EC-1.11.1.6/EC S L5 AND REG/FS S E1 AND LIT/FS	CT FS
Multipunch Codes (3,4)	/MPC	S 134 190 237/MPC S 134 *G 190 *G 237 *G/MPC	MPC
Substructure Term	/SS	S BH-LINKED-CX/SS S QUINOLINE/SS	SS

- (1) To obtain the related literature citations, SELECT DDRN and search the resulting E-number(s) by adding 'AND LIT/FS' (e.g. => S E1 AND LIT/FS).
 (2) Numeric search field that may be searched using numeric operators or ranges.
 (3) Search with implied (L) proximity is available in this field.
 (4) This field is available in the Derwent Subscriber file DRUGU only.

Structure Search Terms (REGISTRY segment in file DRUGU only)

Terms (1)	Search Examples
L-numbers of structures built using the STRUCTURE command or uploaded from STN Express (Boolean logic allowed between the L-numbers)	SEARCH L1 FAM SEA L1 AND L2 SSS FUL S L3 OR L4 SSS
L-numbers of screen sets created using the SCREEN command (Boolean logic allowed between the L-numbers)	S L1 AND L2 NOT L3
L-numbers of structures built using the STRUCTURE command or uploaded from STN Express combined with L-numbers of screen sets created using the SCREEN command (Boolean logic allowed between the L-numbers)	

- (1) The L-number answer set from a structure search may be combined with text terms, e.g. => S L3 AND INHIBITOR#. Refer to the registry search and display fields section of this summary sheet, for more information on text terms.

Scope of Structure Searches

Scope	Definition	Search	Search Examples
Full (default)	Search 100 % of the file.	FUL	S L5 OR L8 SSS FUL
Range	Search a user-specified portion of the file.	RAN	S L3 FAM RAN=(1992-0, 1993-0)
Subset Range	Search a user-specified portion of an answer set created by a search in DRUGU.	SUB RAN	S L3 SUB=L2 RAN=(1996)
Subset Full	Search 100% of an answer set created by a search in DRUGU file.	SUB FUL	S L8 SUB=L6 FAM FUL

Types of Structure Searches (REGISTRY segment in file DRUGU only)

Scope	Definition	Search	Search Examples
Substructure (default)	Search for substances that match the query. Substitution is allowed at all open positions. Additional components maybe retrieved.	SSS	SEARCH L1 SSS FUL S L2 OR L3 SSS S L7 SSS
Closed Substructure	Search for substances that match the query exactly. Substitution is allowed at positions opened by CONNECT. Additional components may be retrieved.	CSS	SEARCH L1 CSS S L2 OR L3 CSS S L4 NOT L5 CSS FUL
Family	Search for substances that match the query exactly. Additional components maybe retrieved.	FAM	S L6 FAM
Exact	Search for substances that match the query exactly.	EXA	SEA L5 EXA FUL

Derwent Drug File Thesaurus

The Derwent Drug File Thesaurus is available online in field /CT (Controlled Term). All relationships codes can be used with both the EXPAND and SEARCH command.

Field	Relationship Code	Content	Search Examples
/CT	ALL AUTO (1) BT HIE NT PFT RT UF USE	All Associated Terms (BT, SELF, USE, UF, SEE, NEW, OLD, TN, EC, CN, RT, NT, NOTE) Automatic Relationship (SELF, USE, UF, SEE, NEW, OLD, TN, EC, CN, NT) Broader Terms (also BT1, BT2 etc. possible) Hierarchy Terms (BT, SELF, NT) Narrower Terms (also NT1, NT2 etc. possible) All Preferred and Forbidden Terms Related Terms (see also) Used for (Preferred and Forbidden Terms) Use Forbidden and Preferred Terms	E LOBAPLATIN+ALL/CT E CLOPIDOGREL+AUTO/CT E LEGIONNAIRE-DISEASE+BT/CT E PNEUMONIA+HIE/CT E CLOPIDOL+PFT/CT E XYLAMIDE+RT/CT E FORMALDEHYDE+UF/CT E FORMALIN+USE/CT

(1) Automatic Relationship is SET OFF. In case of SET REL ON, the result of EXPAND or SEARCH without any relationship code is the same as described for AUTO.

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available for all fields. Highlighting must be ON during SEARCH to use the HIT, KWIC, and OCC formats.

Literature Segment

Format	Content	Examples
AB ABEX (1) AN AU AV CC CS CT DDRN DT (TC) EC FA FS ISN (2) JT (2) LA LO MPC (1) PY (2) RN SH SO TI	Abstract Abstract Extension Accession Number Author Availability of Document (Reprint Address) Classification Code Corporate Source Controlled Term (incl. Enzyme Com. Nos. and CAS Registry Numbers) Derwent Drug Registry Name Document Type Enzyme Commission Number Field Availability File Segment International Standard (Document) Number Journal Title Language Location Multipunch Code Publication Year CAS Registry Number Subject Heading Source (includes AV) Title	D TI AB 1-4 D ABEX DIS AN D AU TI 1-10 D TI AV 1-5 D CC D TI CS AB D CT D DDRN D DT D EC D AN FA D FS D JT ISN D JT D LA D CS LO D MPC D PY D RN D SH D TI AU SO 1-10 D TI 5
ABS ALL IALL BIB CBIB IBIB IND MAX TRIAL (TRI, SAM)	AN, AB, ABEX (1) AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, SH, CC, CT, FA, FS ALL, Indented with text labels AN, TI, AU, CS, LO, SO, AV, LA, DT, FA AN, TI, AU, CS, LO, SO, AV, LA, DT (compressed bibliography) BIB, indented with text labels AN, SH, CC, CT, MPC (1) AN, TI, AU, CS, LO, SO, AV, LA, DT, AB, ABEX (1), SH, CC, CT, MPC (1), FA, FS AN, TI, CC, CT	D ABS D ALL D IALL D BIB D CBIB D IBIB D IND D MAX D TRIAL
HIT KWIC OCC	Hit term(s) and field(s) Up to 50 words before and after hit term(s) (KeyWord-In-Context) Number of occurrences of hit term(s) and field(s) in which they occur	D HIT D KWIC D OCC

(1) This field is available in the Derwent Subscriber file DRUGU only.

(2) Custom display only.

REGISTRY Segment

Format	Content	Examples
AN CT DDN DDRN EC MPC (1) NTE (1,2) RN SS STR (1,2)	Accession Number Controlled Term Derwent Drug Name Derwent Drug Registry Name Enzyme Commission Number Multipunch Code Note CAS Registry Number Substructure Term Structure (includes NTE)	DIS AN D CT D DDN D DDRN D EC D MPC D NTE D RN D SS D ALL STR
ALL IALL IND TRIAL (TRI, SAM)	AN, FS, DDRN, DDN, RN, CT, SS, MPC (1) (ALL is default) ALL, indented with text labels AN, FS, RN, CT, SS, MPC (1) AN, SS	D ALL D IALL D IND D TRIAL
HIT KWIC OCC	Hit term(s) and field(s) Up to 50 words before and after hit term(s) (KeyWord-In-Context) Number of occurrences of hit term(s) and field(s) in which they occur	D HIT D KWIC D OCC

(1) This field is available in the Derwent Subscriber file DRUGU only.

(2) Custom display only

SELECT, ANALYZE, and SORT Fields

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y (2)	N
Abstract Extension	ABEX (3)	Y	N
Accession Number	AN	Y	N
Author	AU	Y	Y
Availability (of Document)	AV	Y	Y
CAS Registry Number	RN	Y	N
Classification Code	CC	Y	Y
CODEN	CODEN	N	Y
Controlled Term	CT	Y	N
Corporate Source	CS	Y	Y
Derwent Drug Name	DDN	Y	Y
Derwent Drug Registry Name	DDRN	Y (4)	N
Document Type	DT (TC)	Y	Y
Enzyme Commission Number	EC	Y	Y
Field Availability	FA	Y (4)	Y
File Segment	FS	Y	Y
International Standard (Document) Number	ISN	Y (5)	Y
International Standard Serial Number	ISSN	N	Y
Journal Title	JT	Y	Y
Language	LA	Y	Y

SELECT, ANALYZE, and SORT Fields (cont'd)

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Location	LO	Y	Y
Multipunch Code	MPC (3)	Y	N
Note	NTE (3)	Y	N
Occurrence Count of Hit Terms	OCC	N	Y
Publication Year	PY	Y	Y
Source	SO	Y (6)	N
Subject Heading	SH	Y	Y
Substructure Term	SS	Y	N
Title	TI	Y (default)	Y

(1) HIT may be used to restrict terms extracted to terms that match the search expression used to create the answer set, e.g., SEL HIT TI.

(2) Appends /BI to the terms created by SELECT.

(3) This field is available in the Derwent Subscriber file DRUGU only.

(4) SELECT HIT and ANALYZEHIT may not be used with this field.

(5) Selects or analyzes CODEN and ISSN with /ISN appended to the terms created by SELECT.

(6) Selects or analyzes CODEN and ISSN with /SO appended to the terms created by SELECT.

Sample Records**DISPLAY IALL**

ACCESSION NUMBER: 1999-01086 DDFU P
 TITLE: Benzoprims: dual action against DHFR and mutant Ki-ras.
 AUTHOR: Stevens M F G; Griffin R J; Richardson M L
 CORPORATE SOURCE: Univ.Nottingham; Univ.Newcastle
 LOCATION: Nottingham; Newcastle, U.K.
 SOURCE: Br.J.Cancer (78, Suppl. 1, 32, 1998) 1 Fig. 2 Reference
 CODEN: BJCAAI ISSN: 0007-0920
 AVAIL. OF DOC.: Cancer Research Laboratories, University of Nottingham, NG7
 2RD, England
 LANGUAGE: English
 DOCUMENT TYPE: Journal

ABSTRACT:

Highly substituted 2,4-diaminopyrimidines (benzoprims) as exemplified by methylbenzoprim 1 and dichlorobezoprim 2 were developed as non-classical lipophilic analogs of methotrexate (MTX) and have potent inhibitory activity against mammalian DHFR (Ki of 10 power -12 M). A panel of lung, colon and pancreatic cell lines were established which were characterised for ras expression in order to redesign the lead benzoprim structure to identify a pure anti-ras molecule. (conference abstract).

SECTION HEADING: P Pharmacology

CLASSIF. CODE: 52 Chemotherapy - non-clinical

CONTROLLED TERM:

COLON *FT; INTESTINE *FT; LUNG *FT; PANCREAS *FT; CARCINOMA
 *FT; MOUSE *FT; IN-VITRO *FT; TUMOR-CELL *FT; TISSUE-CULTURE
 *FT; EKVX-CELL *FT; HOP92-CELL *FT; NCI-H522-CELL *FT;
 A549-CELL *FT; NCIH23-CELL *FT; HClH460-CELL *FT; LAB.ANIMAL
 *FT; TISSUE-CULTURE *FT; ADENOCARCINOMA *FT; TISSUE-CULTURE
 *FT; TUMOR-CELL *FT


[01] METHOBENZAPRIM *PH; METHOBENZ *RN; FOLATE-ANTAGONISTS *FT; PH
 *FT

[02] DR9900056 *RN; NEW *FT; PH *FT

FIELD AVAIL.: AB; LA; CT
FILE SEGMENT: Literature

DISPLAY ALL STR

AN 64138 DRUGU
FS Registry
DDRN DR9900056
SS PYRIMIDINE; GUANIDINE,CYCLIC; AMIDINE,CYCLIC; POLYAMINE; ARYLAMINE;
NITROARENE; ARALKYLAMINE; ARYLCHLORIDE

**DISPLAY MAX**

AN 1999-34705 DDFU P
TI Preclinical evaluation of PEG-L-asparaginase for pancreatic cancer.
AU Denis L J; Izbicka E; Davidson K; Lawrence R; Marty J; Barrera H; Medina
L; Moore R; Weitman S; Von Hoff D D
CS Cancer-Therapy-Res.Cent.San-Antonio
LO San Antonio, Tex., USA
SO Proc.Am.Assoc.Cancer Res. (40, 90 Meet., 343-44, 1999) ISSN:
0197-016X
AV Institute for Drug Development, Cancer Therapy and Research Center, San
Antonio, TX 78245, U.S.A.
LA English
DT Journal
AB The aim of this study was to evaluate a polyethylene glycol modified L-
asparaginase (PEG-L-ASNase, Oncaspar) in combination with gemcitabine in
vitro and in vivo using mice. PEG-L-ASNase demonstrated significant
inhibition of 3 human pancreatic cell lines in vitro and an additive
effect was observed with gemcitabine. PEG-L-ASNase and gemcitabine
exhibited additive tumor growth inhibition in the murine xenograft model.
In conclusion, these data indicate that PEG-L-ASNase is a promising new
drug formulation for the treatment of pancreatic cancer and warrants
further study particularly in combination with gemcitabine. (conference
abstract: 90th Annual Meeting of the American Association for Cancer
Research, Philadelphia, Pennsylvania, USA, 1999).
SH P Pharmacology
CC 52 Chemotherapy - non-clinical
65 Drug Delivery
CT PANCREAS *OC; ANIMAL-NEOPLASM *OC; PANCREOPATHY *OC; IN-VIVO *FT;
IN-VITRO *FT; CYTOSTATIC *FT; TUMOR-CELL *FT; MOUSE *FT; I.P. *FT;
ADDITIVE *FT; SYNERGIST *FT; CYTOSTATIC-COMB. *FT; XENOGRAFT *FT;

DDFU/DRUGU

TISSUE-CULTURE *FT; LAB.ANIMAL *FT; INJECTION *FT; COMB. *FT
 [01] ASPARAGINASE *PH; POLYETHYLENE-GLYCOL *PH; ASPARASE *RN; DRUG-DELIVERY
 *FT; ONCASPAR *FT; CYTOSTATICS *FT; ENZYMES *FT; EC-3.5.1.1 *FT; PH
 *FT
 RN: 9015-68-3
 [02] GEMCITABINE *PH; LY-188011 *RN; CYTOSTATICS *FT; PH *FT
 RN: 95058-81-4

FA AB; LA; CT
 FS Literature

DISPLAY BIB

AN 2000-10723 DDFU T
 TI Low-dose methotrexate in the treatment of patients with primary
 anti-phospholipid syndrome.
 AU Boehm I; Bauer R; Bieber T
 CS Univ.Bonn
 LO Bonn, Ger.
 SO Z.Hautkr. (74, Number 10, 623, 1999)
 CODEN: ZHKRAJ ISSN: 0301-0481
 AV Klinik und Poliklinikfuer Dermatologie der Universitaet Bonn, Bonn,
 Deutschland.
 LA German
 DT Journal
 FA AB; LA; CT
 FS Literature

In Europe
 FIZ Karlsruhe
 STN Europe
 P.O. Box 2465
 76012 Karlsruhe
 Germany
 Phone: +49-7247-808-555
 Fax: +49-7247-808-259
 E-mail: helpdesk@fiz-karlsruhe.de
 Internet: www.stn-international.com

In North America
 CAS
 STN North America
 P.O. Box 3012
 Columbus, Ohio 43210-0012 U.S.A.
 CAS Customer Center:
 Phone: 800-753-4227 (North America)
 614-447-3700 (worldwide)
 Fax: 614-447-3751
 E-mail: help@cas.org
 Internet: www.cas.org

In Japan
 JAICI (Japan Association for
 International Chemical Information)
 STN Japan
 Nakai Building
 6-25-4 Honkomagome, Bunkyo-ku
 Tokyo 113-0021, Japan
 Phone: +81-3-5978-3601 (Technical Service)
 +81-3-5978-3621 (Customer Service)
 Fax: +81-3-5978-3600
 E-mail: support@jaici.or.jp (Technical Service)
 customer@jaici.or.jp (Customer Service)
 Internet: www.jaici.or.jp